Signal transduction pathways in sarcoma as targets for therapeutic intervention

Current Opinion in Oncology

Volumn 13, Issue 4, 2001, Pages 249-255

  Tuveson, David A ^a,b   Fletcher, Jonathan A ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE;

CHROMOSOME TRANSLOCATION; DERMATOFIBROSARCOMA PROTUBERANS; DESMOPLASTIC SMALL ROUND CELL TUMOR; FIBROSARCOMA; GASTROINTESTINAL TUMOR; GENE TARGETING; GENETIC LINKAGE; HUMAN; MESOBLASTIC NEPHROMA; NEUROFIBROMATOSIS; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; SARCOMA; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS;

EID: 0034949674     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200107000-00007     Document Type: Review

References (80)

1. Gastrointestinal stromal tumors: Recent advances in understanding of their biology
2. Biological and clinical review of stromal tumors in the gastrointestinal tract
3. A clinicopathologic and immuno-histochemical study of gastrointestinal stromal tumors
4. Contrast of response to D-MAP+ sargramostim between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas
5. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival
6. Gastrointestinal stromal tumours: An update
7. CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34
8. Mesenchymal tumors of the gastrointestinal tract: A paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cells of Cajal in the pathogenesis of gastrointestinal diseases?
9. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal
10. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors
11. Developmental origin and Kit-dependent development of the interstitial cells of Cajal in the mammalian small intestine
12. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
13. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
14. Activating c-kit gene mutations in human germ cell tumors
15. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders
16. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
17. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors
18. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors
19. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas
20. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors
21. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene
22. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
23. Inhibition of the Abl protein tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
24. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins
25. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
26. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571
27. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor
28. Clinical efficacy and safety of an abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
29. STI571 inactivation of the gastrointestinal strom tumor c-KIT oncoprotein: Biological and clinical implications
30. Clinical response induced by the tyrosine kinase inhibitor STI571 in metastatic gastrointestinal stromal tumor expressing a mutant c-kit proto-oncogene
31. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases
32. Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: An historical review with differential diagnostic considerations
33. Inflammatory myofibroblastic tumor: Cytogenetic evidence supporting clonal origin
34. Clonal changes in inflammatory pseudotumor of the lung: A case report
35. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors
36. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
37. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation
38. Chromosome aberrations in mesoblastic nephroma
39. Fibrosarcoma in infants and children. Application of new techniques
40. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
41. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma
42. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: Cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma
43. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors
44. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells
45. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma
46. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas
47. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
48. Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals
49. Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): Desmoplastic small round-cell tumor and its variants
50. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor
51. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour
52. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation
53. NF1 tumor suppressor gene function: Narrowing the GAP
54. Pathology of the major peripheral nerve sheath neoplasms
55. Neurofibromatosis and cancer
56. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations
57. Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients
58. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus
59. Loss of NF1 alleles in phaeochromocytomas from patients with type 1 neurofibromatosis
60. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis
61. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders
62. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene
63. Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma
64. Schwann cells harbor the somatic NF1 mutation in neurofibromas: Evidence of two different Schwann cell subpopulations
65. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins
66. The neurofibromatosis type 1 gene encodes a protein related to GAP
67. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
68. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae
69. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients
70. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis
71. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells
72. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors
73. Understanding Ras: 'It a'int over 'til it's over'
74. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
75. Farnesyltransferase inhibitors: Targeting the molecular basis of cancer
76. The therapeutic potential of ribozymes
77. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo
78. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors